Latest Financial Results
Q2 2022
Quarter Ended Jun 30, 2022
$269.7M
Total revenue of $269.7 million, up 54% from $175.6 million for the prior-year quarter
$11.4M
Net income attributable to ApolloMed of $11.4 million, compared to $12.7 million for the prior-year quarter
$0.25
Earnings per share - diluted ("EPS - diluted") of $0.25, compared to $0.28 per share for the prior-year quarter
For complete information regarding our financials, see our periodic filings